Skerra A - Search Results

1

Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer.

Peplau E, De Rose F, Reder S, Mittelhäuser M, Scafetta G, Schwaiger M, Weber WA, Bartolazzi A, Skerra A, D'Alessandria C. Peplau E, et al. Among authors: skerra a. Thyroid. 2020 Sep;30(9):1314-1326. doi: 10.1089/thy.2019.0670. Epub 2020 Apr 30. Thyroid. 2020. PMID: 32200708

2

High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.

Mendler CT, Friedrich L, Laitinen I, Schlapschy M, Schwaiger M, Wester HJ, Skerra A. Mendler CT, et al. Among authors: skerra a. MAbs. 2015;7(1):96-109. doi: 10.4161/19420862.2014.985522. MAbs. 2015. PMID: 25484039 Free PMC article.

3

⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.

Mendler CT, Gehring T, Wester HJ, Schwaiger M, Skerra A. Mendler CT, et al. Among authors: skerra a. J Nucl Med. 2015 Jul;56(7):1112-8. doi: 10.2967/jnumed.114.149690. Epub 2015 May 21. J Nucl Med. 2015. PMID: 25999431 Free article.

4

Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion.

Mendler CT, Feuchtinger A, Heid I, Aichler M, D'Alessandria C, Pirsig S, Blechert B, Wester HJ, Braren R, Walch A, Skerra A, Schwaiger M. Mendler CT, et al. Among authors: skerra a. J Nucl Med. 2016 Dec;57(12):1971-1977. doi: 10.2967/jnumed.116.176784. Epub 2016 Jul 14. J Nucl Med. 2016. PMID: 27417649 Free article.

5

Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models.

Friedrich L, Kornberger P, Mendler CT, Multhoff G, Schwaiger M, Skerra A. Friedrich L, et al. Among authors: skerra a. Biol Chem. 2018 Feb 23;399(3):235-252. doi: 10.1515/hsz-2017-0207. Biol Chem. 2018. PMID: 29140786

6

Development of a high affinity Anticalin^® directed against human CD98hc for theranostic applications.

Deuschle FC, Morath V, Schiefner A, Brandt C, Ballke S, Reder S, Steiger K, Schwaiger M, Weber W, Skerra A. Deuschle FC, et al. Among authors: skerra a. Theranostics. 2020 Jan 12;10(5):2172-2187. doi: 10.7150/thno.38968. eCollection 2020. Theranostics. 2020. PMID: 32089738 Free PMC article.

7

First In-Human Medical Imaging with a PASylated ⁸⁹Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer.

Richter A, Knorr K, Schlapschy M, Robu S, Morath V, Mendler C, Yen HY, Steiger K, Kiechle M, Weber W, Skerra A, Schwaiger M. Richter A, et al. Among authors: skerra a. Nucl Med Mol Imaging. 2020 Apr;54(2):114-119. doi: 10.1007/s13139-020-00638-7. Epub 2020 Apr 20. Nucl Med Mol Imaging. 2020. PMID: 32377263 Free PMC article.

8

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.

Heider M, Eichner R, Stroh J, Morath V, Kuisl A, Zecha J, Lawatscheck J, Baek K, Garz AK, Rudelius M, Deuschle FC, Keller U, Lemeer S, Verbeek M, Götze KS, Skerra A, Weber WA, Buchner J, Schulman BA, Kuster B, Fernández-Sáiz V, Bassermann F. Heider M, et al. Among authors: skerra a. Mol Cell. 2021 Mar 18;81(6):1170-1186.e10. doi: 10.1016/j.molcel.2020.12.046. Epub 2021 Feb 10. Mol Cell. 2021. PMID: 33571422 Free PMC article.

9

Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo.

Peplau E, De Rose F, Eichinger A, Reder S, Mittelhäuser M, Scafetta G, Schwaiger M, Weber WA, Bartolazzi A, D'Alessandria C, Skerra A. Peplau E, et al. Among authors: skerra a. Sci Rep. 2021 Apr 1;11(1):7358. doi: 10.1038/s41598-021-86641-0. Sci Rep. 2021. PMID: 33795750 Free PMC article.

10

Molecular Design of ⁶⁸Ga- and ⁸⁹Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors.

Morath V, Brandt C, Deuschle FC, Mendler CT, Blechert B, Summer D, Barinka C, Decristoforo C, Weber WA, Schwaiger M, Skerra A. Morath V, et al. Among authors: skerra a. Mol Pharm. 2023 May 1;20(5):2490-2501. doi: 10.1021/acs.molpharmaceut.2c01066. Epub 2023 Apr 17. Mol Pharm. 2023. PMID: 37068305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page